Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05025956 · ClinicalTrials.gov registry record · Phase 1
Senolytic Agent Improve the Benefit of Platelet-Rich Plasma and Losartan
A Phase 1 study of Femoroacetabular Impingement, sponsored by Steadman Philippon Research Institute.
- Active
- Registry status
- Phase 1
- Development phase
- 68
- Enrollment target
- 1
- Study location
NCT05025956 is a Phase 1 study of Femoroacetabular Impingement that is active but no longer recruiting, run by Steadman Philippon Research Institute. The registered enrollment target is 68 participants, below the 2,535-participant average among 4 other Femoroacetabular Impingement trials with a reported enrollment target (97% lower). The trial reports 1 study location across 1 state.
The verdict
NCT05025956, a Phase 1 study of Femoroacetabular Impingement, is active but no longer recruiting, sponsored by Steadman Philippon Research Institute.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 68 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose is to explore the possible benefit of administration of Fisetin, (a senolytic agent) to improve the benefit of Platelet-Rich Plasma and losartan for treatment of femoroacetabular impingement and labral tear. We believe that giving Fisetin, a senolytic agent, will improve the benefit of PRP by eliminating senescent cells and senescence-associated secretory phenotype (SASP), known to exist in PRP. The main objectives of this study are to determine if pre- and post-operative administration of a senolytic agent will improve the beneficial effects of PRP when used in conjunction with surgical treatment of FAI and/or labral tear, to determine whether pre- and postoperative administration of Fisetin is associated with adverse events, and to determine if pre- and post-operative administration of Fisetin leads to a decrease in systemic senescence, serum SASP, and fibrotic markers. Patients suffering from femoroacetabular impingement and labral tear, who are planning to undergo hip arthroscopy combined with standard of care intra-operative PRP injection and post-operative losartan administration will be recruited from the clinical practice of the Principal Clinical Investigator or his designee at The Steadman Clinic (TSC).
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Fisetin
Study Locations (1)
Colorado
- The Steadman Clinic - Vail
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 68 participants |
| Start Date | 2021-10-24 |
| Est. Completion | 2024-10-31 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05025956
The ClinicalTrials.gov registry entry for NCT05025956 describes a study currently listed as active not recruiting, categorized as Phase 1. The registered enrollment target is 68 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 2,535-participant average among 4 other Femoroacetabular Impingement trials with a reported enrollment target (97% lower). The listed sponsor is Steadman Philippon Research Institute, which has 7 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Femoroacetabular Impingement appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT05025956 reports 1 study location spanning 1 distinct geographic area - top geographies include Colorado.
Frequently Asked Questions
What is clinical trial NCT05025956 about?
NCT05025956 is a clinical study titled "Senolytic Agent Improve the Benefit of Platelet-Rich Plasma and Losartan". The purpose is to explore the possible benefit of administration of Fisetin, (a senolytic agent) to improve the benefit of Platelet-Rich Plasma and losartan for treatment of femoroacetabular impingement and labral tear. We believe that giving Fisetin, a senolytic agent, will improve the benefit of ...
What is the current status of trial NCT05025956?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 68 participants. The study started on 2021-10-24. Estimated completion is 2024-10-31.
What conditions does trial NCT05025956 study?
This clinical trial studies the following conditions: Femoroacetabular Impingement.
What interventions are being tested in trial NCT05025956?
The interventions under investigation include: Placebo (DRUG), Fisetin (DRUG).
Who is sponsoring clinical trial NCT05025956?
This trial is sponsored by Steadman Philippon Research Institute, which has 7 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05025956 being conducted?
This trial has 1 study location across Colorado. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Femoroacetabular Impingement
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.